moneyheap
BLCO · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Bausch + Lomb Corporation (BLCO) stock moving?
BLCO's Q3 2026 report on Oct 28 was a clear beat: revenue of $1.375B (up 7% as reported, 8% constant currency) against a $1.373B estimate, adjusted EPS of $0.34 against $0.22, and GAAP net income of $32M. Management raised full-year sales guidance to $5.450B-$5.550B, above the $5.496B consensus, and raised adjusted EBITDA excluding acquired IPR&D guidance. Segment growth was strong: MIEBO revenue rose 42%, LUMIFY 35%, premium IOLs about 70%, and the Daily SiHy portfolio 24%. The stock jumped from a $17.62 close to $20.40 on Oct 28 (+15.8%) on 4.1M shares, roughly six times the prior daily volume, and it has since held above $20. Analysts followed with mostly higher targets: RBC raised to $23 (Outperform), JP Morgan to $22 (Neutral) and Wells Fargo to $19 (Equal-Weight). HC Wainwright downgraded to Neutral on Nov 2 while lifting its target to $22. Negatives include the Oct 28 8-K: Board member Nathalie Bernier resigned, the Board does not plan to fill the seat, and Chairman Thomas Appio became interim CEO after Brent Saunders' departure was agreed. Also, the CAO sold about $2.29M of shares on Nov 2, and Bausch Health, the parent, is discussing strategic options for its stake. The Nov 10 close of $21.37 is the highest in the 30-day window, on 1.5M shares, but it now sits above the Wells Fargo target and near the RBC, JP Morgan and HC Wainwright targets, which limits consensus upside.
News behind the analysis
- Bausch + Lomb Reports Third-Quarter 2026 Financial Results and Raises Full-Year GuidanceQ3 2026 revenue rose 7% as reported to $1.375B, with growth in all three segments. Full-year 2026 revenue and adjusted EBITDA excluding acquired IPR&D guidance were raised.
- Bausch & Lomb Q3 Adj. EPS $0.34 Beats $0.22 Estimate, Sales $1.375B Beat $1.373B EstimateAdjusted EPS of $0.34 beat the $0.22 consensus, and sales of $1.375B slightly beat the $1.373B estimate.
- Bausch & Lomb Raises FY2026 Sales Guidance from $5.440B-$5.540B to $5.450B-$5.550B vs $5.496B EstThe company lifted its FY2026 sales guidance range to $5.450B-$5.550B, above the $5.496B consensus midpoint of the prior range.
- Analysts Raise Price Targets for Bausch + Lomb Following Q3 EarningsRBC, Leerink Partners and Jefferies raised their price targets on Oct 29 after the Q3 report. FactSet's survey of 14 analysts also raised 2026 EPS estimates.
- RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $23RBC kept its Outperform rating and raised its price target to $23 after Q3 results.
- JP Morgan Maintains Neutral on Bausch & Lomb, Raises Price Target to $22JP Morgan kept a Neutral rating and lifted its price target to $22.
- Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19Wells Fargo kept an Equal-Weight rating and raised its price target to $19, which is below the current share price.
- HC Wainwright Downgrades Bausch + Lomb to Neutral from BuyHC Wainwright downgraded BLCO to Neutral from Buy while raising its price target to $22 from $21.
- Bausch + Lomb SVP and CAO Frederick Munsch Sells SharesFrederick Munsch, SVP, Controller and Chief Accounting Officer, sold 112,015 shares for about $2.29 million.
- Bausch Health Discusses Strategic Options for Bausch + LombOn its Q3 2026 earnings call, Bausch Health addressed potential strategic options for its ownership stake in Bausch + Lomb.
About Bausch + Lomb Corporation
Bausch + Lomb is a global eye-health company based in Vaughan, Ontario, and listed on the NYSE and TSX. It sells contact lenses, lens-care products, eye drops, prescription eye medicines and cataract-surgery products, and Bausch Health (BHC) still owns most of its shares.
How it makes money
The company has three segments. Vision Care is the largest, bringing in roughly half of revenue from contact lenses (including daily silicone hydrogel lenses), lens-care solutions and consumer eye products like Lumify drops and eye vitamins. Surgical sells intraocular lenses (including premium IOLs), equipment and consumables for cataract and vision-correction surgery. Pharmaceuticals sells prescription eye drugs, including the dry-eye treatment Miebo. The company expects roughly $5.5 billion in 2026 revenue.
What usually moves BLCO
- Growth of key products like Miebo, Lumify, daily contact lenses and premium IOLs
- Paying down debt and the cost of a large debt load
- Decisions by majority owner Bausch Health and any separation plans
- FDA decisions and pipeline news, such as the dry AMD drug candidate
- Exchange-rate swings on international sales